Fresenius Kabi confirmed the availability of Bortezomib for injection in the United States. Fresenius Kabi Bortezomib for Injection is available as a single dose vial containing 3.5 mg of lyophilized powder. A Global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition.
Fresenius Kabi Bortezomib for Injection is available as a single dose vial containing 3.5 mg of lyophilized powder claimed “Fresenius Kabi Bortezomib is a cost efficient product alternative for our customers and the patients they treat. We are proud to offer an expansive oncology portfolio and will continue to develop these essential medicines.”
The injection is mainly hinted at treatment of patients with multiple myeloma and for the treatment of patients with mantle cell lymphoma having obtained at least 1 prior therapy.
Image source : Fresenius Kabi